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impact of these in a big corporation in Hong Kong from
an employer’s perspective.
METHODS: A questionnaire to study the 11,000 em-
ployees of a Hong Kong-based major international airline
company was developed. The two major categories of
employees surveyed were the ground staff and the flight
crew due to different working environments and thus dif-
ferent risk factors for flu. The questionnaire captured in-
formation on the age, sex, years of service, grade and
number of episodes in the past 12 months. Information
about the nature and duration and of the effects on the
well being of the individual during each episode was ob-
tained. The need for medical treatment and days off was
also documented.
RESULTS: Eleven thousand questionnaires were sent out
and 2,212 were returned (response rate 20.1%). Among
the flight crew, each member of the cockpit and cabin
crews was estimated to lose on average 14.4 and 13.0
“equivalent days of perfect health” (EDPH) per year re-
spectively. For the ground staff, each member of the
check-in and back-office staff was estimated to lose 6.9
EDPH and 8.7 EDPH per year respectively. In terms of
productivity, depending on the salary-scale of the staff,
between HK$2,321 (check-in staff), (1US$  7.8HK$),
and HK$36,791 (cockpit crew) was lost per year per
worker. Evidence indicated that a disproportionately
large proportion of the flu episodes among aircrew oc-
curred during or after a trip to Europe and S.E. Asia.
CONCLUSION: The impact of FFLIs on flight crew ap-
pears to be greater than the impact on ground staff.
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OBJECTIVE: A double-blind, randomized, multicenter
clinical study comparing ciprofloxacin/metronidazole (CIP/
MET) versus piperacillin/tazobactam (PIP/TAZO) in hospi-
talized adult patients (pts) with severe intra-abdominal in-
fections was the basis for this pharmacoeconomic analysis.
METHODS: A cost-effectiveness analysis from a hospital
provider perspective was conducted. Cost-effectiveness
ratios (CER) were calculated.
RESULTS: Among 276 evaluable pts, 148 received CIP/
MET and 128 received PIP/TAZO. IV-PO: 65% (96/148)
CIP/MET and 59% (75/128) PIP/TAZO pts were switched
to oral administration. IV-PO CIP/MET pts with appendi-
citis had an 89% success rate; mean treatment duration
was 6.4 
 3.4 days and mean CER was US$7,696. Similar
pts who received PIP/TAZO had a 68% success rate;
mean treatment duration was 5.4 
 2.7 days and mean
CER was US$10,372. IV-PO CIP/MET non-appendicitis
pts had an 83% success rate; mean treatment duration
was 7.7 
 2.6 days and mean CER was US$11,114. Sim-
ilar pts who received PIP/TAZO had a 72% success rate;
mean treatment duration was 8.5 
 4.8 days and mean
CER was US$13,331. IV Only: CIP/MET appendicitis pts
had a success rate of 87%; mean therapy duration was
5.0 
 2.2 days and mean CER was US$7,328. Similar pts
who received PIP/TAZO had a 56% success rate; mean
treatment duration was 6.4 
 3.1 days and mean CER
was US$10,980. Non-appendicitis CIP/MET pts had a
success rate of 45%; mean therapy duration was 13.3 

9.5 days and mean CER was US$17,881. Similar pts who
received PIP/TAZO had a 52% success rate; mean treat-
ment duration was 11.6 
 8.2 days and mean CER was
US$17,944. Sensitivity analysis revealed that PIP/TAZO
needed to be 10 to15% more successful in order to be
cost-effective.
CONCLUSION: Whether pts had appendicitis or not,
and whether they could be switched to oral antibiotics or
not, the combination of ciprofloxacin/metronidazole was
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OBJECTIVES: To compare three-years costs and effects
of terbinafine 250 mg/d for 12 or 16 weeks (T12, T16)
and itraconazole 400 mg/d for 1 week every 4 weeks for
12 or 16 weeks (I3, I4) and select the optimal treatment
strategy for toenail onychomycosis in Poland.
METHODS: Data from the literature (a search of Med-
line reports with time horizon 1 year, intent-to-treat
design) were used to estimate the mycological cure rate.
Direct medical costs were estimated on the basis of cur-
rent treatment patterns in Poland. The perspective of the
health-care payers (sick fund and patients) and a time ho-
rizon of three years were taken. Costs and effects of the
treatment strategies were modeled using six scenarios,
which attempt to reflect real-life practice: T12 or T16 as
primary treatment, I3 as treatment of failure and T12 or
I3 as treatment of re-infection (T12/I3,T12; T12/I3,I3;
T16/I3,T12; T16/I3,I3) and I3 or I4 as primary treat-
ment, T12 as treatment of failure and re-infection (I3/
T12, T12; I4/T12, T12). One-way sensitivity analysis and
threshold analyses were performed.
RESULTS: The mean cost/mycological cure (in PLN, 1
USD  4 PLN) were: 1925 for T12/I3,T12; 1986 for
T12/I3,I3; 2175 for T16/I3,T12; 2244 for T16/I3,I3;
2375 for I3/T12,T12 and 2477 for I4/T12,T12. The
strategy T12/I3,I3 was dominated by T12/I3,T12. The
Abstracts 445
strategies T16/I3,I3 and I3/T12,T12 were dominated by
T16/I3,T12. The incremental analysis vs. strategy T12/
I3,T12 indicated, that T16/I3,T12 and I4/T12,T12 were
not cost-effective alternatives for T12/I3,T12 with ICER
14 743 and 19 687 PLN/mycological cure gained, respec-
tively. Changing the values of key drivers in the sensitiv-
ity analysis did not have any significant effect on ICER.
CONCLUSION: T12 as primary treatment with I3 as
treatment of failure and T12 as treatment of re-infection
was the most cost-effective treatment for toenail onycho-
mycosis in Poland.
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OBJECTIVE: Upper respiratory tract infections are fre-
quent in children. Their economic impact is widely un-
known. This study responded to a request from the
French Economic Committee to estimate the direct cost
of an acute rhino-pharyngitis (ARP), the effectiveness of
Imocur® (OM-85 BV indicated for the prevention of re-
currences), and the cost effectiveness of this strategy com-
pared to placebo from a Social Security perspective.
METHOD: Costs, probabilities of short-term complica-
tions, associated care, effectiveness of Imocur during the
winter period were based on review of the literature, na-
tional health statistics and consulting experts’ opinions.
An incremental cost-effectiveness model was used.
RESULTS: The mean direct cost for an ARP is €49.5.
Among children with recurrent infection, 1.52 infections
during the winter period is avoided using this type of pre-
vention and Social Security saves approximately €68 per
child on the cost of care. The sensitivity analyses confirm
the robustness of the model, and show that prevention
with Imocur allowed Social Security to save between 28
and 304 € in direct costs for each at-risk individual who
received preventive treatment. The threshold analysis
shows that this type of prophylaxis is economically prof-
itable for the community starting from 0,15 prevented in-
fections and direct costs of care of an acute infection
exceeding 4.77 €. The demonstration is valid with recur-
rently-infected children, a population for which the effec-
tiveness of Imocur has been established. If we had taken
into account other payers’ viewpoints and the indirect
costs, our conclusions would have been reinforced.
CONCLUSION: Non-specific immunotherapy is a rea-
sonable measure to be considered for prevention of recur-
rences and should be associated with recommended mea-
sures in children at risk. The French health authorities
considered the economic value of an effective medication
to the community in assessing its usefulness.
PIN18
DIRECT AND INDIRECT COSTS OF 
RESPIRATORY INFECTIONS
Birnbaum HG1, Greenberg P1, Morley MA1, Colice GL2
1Analysis Group/Economics, Cambridge, MA, USA; 
2Washington Hospital Center, Washington, DC, USA
OBJECTIVES: Morbidity due to respiratory infections
leads to significant adverse societal and economic conse-
quences. This study investigates the extent to which treat-
ment for respiratory infections imposes a financial burden
on an employer, and documents variations in employer
payments between specific respiratory infections.
METHODS: The data source is a rich administrative
claims database for a national, Fortune 100 manufac-
turer. It includes 1997 medical, pharmaceutical, and dis-
ability claims for employees, spouses, dependents, and re-
tirees (n  100,000) under age 65. The research sample
consists of individual patients with one or more medical
or disability claims for at least one of eleven infectious re-
spiratory conditions. Resource utilization is contrasted
with a 10 percent random sample of the employer’s over-
all beneficiary population.
RESULTS: Direct (medical and pharmaceutical) and in-
direct (disability and sporadic absenteeism) costs are an-
alyzed. The average per capita annual costs are: for the
entire employer population, $2,368; for all respiratory-
infection patients, $4,397, and for respiratory-infection
employees eligible for disability, $6,838. Total costs for
respiratory-infection patients are 1.8 times those for the
typical beneficiary. Total costs are highest for patients
with pneumonia ($11,544) and lowest for patients with
acute tonsillitis and acute pharyngitis ($2,180). Medical
and pharmaceutical treatments account for 65% of total
costs for all employees with respiratory infections, while
the remaining 35% of costs are attributable to disability
and sporadic absenteeism.
CONCLUSIONS: Respiratory infections impose a signif-
icant financial burden on the employer. Resource utiliza-
tion by respiratory infection patients is substantial, not
only for the direct treatment of respiratory infections, but
also for the treatment of co-morbid medical conditions of
these patients. These costs also vary considerably by type
of respiratory infection. The study also shows that respi-
ratory infections impose substantial indirect costs on em-
ployers from work loss associated with these infections.
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